Date:	12/30/2021
Your Name:	Elizabeth Staley
Manuscript Title:	Extracorporeal Corporeal Membrane Oxygenation: Narrative Review of Indications, Technical Considerations, and Future Trends
Manuscript Number (if known):	AOB-2021-TTPP-18

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: Certify that I have answered every question and have not altered the wording of any of the questions on this form			

Date:	12/27/2021
Your Name:	Geoffrey D Wool
Manuscript Title:	Extracorporeal Corporeal Membrane Oxygenation: Narrative Review of Indications, Technical Considerations, and Future Trends
Manuscript Number (if known):	AOB-21-85

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			es with whom you have this indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Non	Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	Time name, past 30 month	
3	Royalties or licenses	None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
		Diagnostica Stago	Payments to me
5	Payment or honoraria for lectures, presentations, speakers	□ None AACC CAP	Payments to me Payments to me
	bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	⊠ None	
pendir	pending		
9	a Data Safety Monitoring	None Non	
	Board or Advisory Board		
10	Leadership or fiduciary role in	□ None	
	other board, society, committee or advocacy group, paid or unpaid	Associate editor, AJCP Editorial board, Blood Coagulation & Fibrinolysis	No financial support No financial support

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			
\boxtimes	I certify that I have	answe	ered every question and have not altered the wo	ording of any of the questions on this form.

Dr. Wool reports honoraria from Diagnostica Stago and travel reimbursements from AACC and CAP. Dr. Wool serves in an unpaid capacity as Associate Editor for AJCP and as an Editorial Board Member of Blood Coagulation & Fibrinolysis.

Date:	1/3/2022
Your Name:	Huy P. Pham
Manuscript Title:	Extracorporeal Corporeal Membrane Oxygenation: Narrative Review of Indications, Technical Considerations, and Future Trends
Manuscript Number (if known):	AOB-2021-TTPP-18

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	□ None Elsevier	Self

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
		Sanofi	Self
5	Payment or	□ None	
	honoraria for lectures,	Alexion	Self
	presentations, speakers		
	bureaus, manuscript writing or educational events		
6	Payment for expert testimony	⊠ None	
7	Support for attending	⊠ None	
	meetings and/or travel		
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring	None ■	
	Board or Advisory Board		
10	Leadership or fiduciary role in	□ None	
	other board,	FACT, Board of Director	Self
	society, committee or		
	advocacy group, paid or unpaid		

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			
\boxtimes	I certify that I have	answe	ered every question and have not altered the wo	rding of any of the questions on this form.

Dr. Pham reports royalties from Elsevier, consulting fees from Sanofi and payment from Alexion. Dr. Pham also serves in an unpaid capacity as Director of Board of FACT.

3 8/26/2021 ICMJE Disclosure Form

Date:			1/3/2022		
Your Name:			Heidi J. Dalton		
Manuscript Title:			Extracorporeal Corporeal Membrane Oxygenation: Narrative Review of Indications, Technical Considerations, and Future Trends		
Manuscript Number (if known):		nown):	AOB-2021-TTPP-18		
content of your manuscript. "Relate affected by the content of the manu			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so.		
epi	·	nsion, you		example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ No	one	Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	⊠ No	Time frame: past 36 month		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	□ No	Time frame: past 36 month		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	□ No Dept of Entegri	Time frame: past 36 month	s Institution (pending)	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None Entegrion (advisor) Medtronic (strategic advisory group) Hemocue (advisor)	\$e\$eIf seIf self
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	UT Southwestern St Christopher Hosp for Children	Self slef
6	Payment for expert testimony	None Non	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Dr. Dalton received funding from Entegrion and royalties from Sccm. Dr. Dalton reports consulting fees from Entegrion, Medtronic and Hemocue as advisor. Dr. Dalton receives payment from UT Southwestern and St Christopher Hosp for Children.

Date:	12/27/2021
Your Name:	Edward C.C. Wong
Manuscript Title:	Extracorporeal Corporeal Membrane Oxygenation: Narrative Review of Indications, Technical Considerations, and Future Trends
Manuscript Number (if known):	AOB-21-85

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present	□ None	
	manuscript (e.g.,	Quest Diagnostics	Employee
	funding, provision of study materials,		
	medical writing,		Click the tab key to add additional rows.
	article processing		
	charges, etc.)		
	No time limit for		
	this item.		
		Time frame: past 36 mont	hs
2	Grants or	□ None	
	contracts from		
	any entity (if not	NIH/NCI grant for NCCAPS study	Payments for coagulation testing to Quest
	indicated in item #1 above).		Diagnostics, no direct payments to me
		Siemens Heathineer	Payments for VWF activity study to Quest
			Diagnostics, no direct payments to me
			Diagnosties, no direct payments to me
		Terumo BCT	Payments for coagulation testing of freeze
		Terumo BCT	
			Payments for coagulation testing of freeze dried plasma to Quest Diagnostics, no direct payments to me.
		Terumo BCT Alexion	Payments for coagulation testing of freeze dried plasma to Quest Diagnostics, no direct

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	⊠ None	
		AACC	Book royalties for Pediatric Reference Interval, 7 th edition
		Elsevier	Book royalities for Pediatric Reference Interval, 8 th edition, and Biochemical and Molecular Basis of Pediatric Disease, 5 th edition
4	Consulting fees	None	
5	Payment or honoraria for lectures,	□ None	
	presentations, speakers		
	bureaus, manuscript writing or educational events		
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None ■	
8	Patents planned,	None	
8	issued or pending	US 9,541,482 B2 "Device and method for bilirubin photoisomerization to reduce laboratory test interference" January 10, 2017.	
9	Participation on a Data Safety	None	
	Monitoring Board or Advisory Board		
	AUVISULY DUALU		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	AACC adhoc committee for pediatric reference intervals, as part of the government affairs committee ASFA Research committee member ASFA Applications committee member AACC, member, publications committee AACC Capital Section, Awards Committee member AACC, Hematology Division, Executive committee member AACC Liaison for the IFFC Task force on Reference	No payments No payments No payments No payments No payments No payments No payments	
		Interval Database	No payments	
11	Stock or stock options	None Quest Diagnostics ■		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None		
13	Other financial or non-financial interests	None		
Please place an "X" next to the following statement to indicate your agreement:				
\boxtimes	☐ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Dr. Wong reports that he is employee and holds stock of Quest Diagnostics.

Dr. Wong also reports payments for coagulation testing to Quest Diagnostics by NIH/NCI grant for NCCAPS study, payments for VWF activity study to Quest Diagnostics by Siemens Heathineer, payments for coagulation testing of freeze dried plasma to Quest Diagnostics by Terumo BCT and Payments for coagulation testing to Quest Diagnostics by Alexion, but no direct payments to Dr. Wong for all items above.

Dr. Wong also reports book royalties for Pediatric Reference Interval, 7th edition by AACC and book royalities for Pediatric Reference Interval, 8th edition, and Biochemical and Molecular Basis of Pediatric Disease, 5th edition by Elsevier.

Dr. Wong reports patent US 9,541,482 B2 "Device and method for bilirubin photoisomerization to reduce laboratory test interference" January 10, 2017.

Dr. Wong also serves in an unpaid capacity as member of the following committees: AACC adhoc committee for pediatric reference intervals (as part of the government affairs committee), ASFA Research committee, ASFA Applications committee, AACC member of publications committee, Awards Committee of AACC Capital Section, Executive committee of Hematology Division of AAC, and AACC Liaison for the IFFC Task force on Reference Interval Database.